Genistein To Decrease Matrix Metalloproteinase-2 (Mmp-2) And Matrix Metalloproteinase-9 (Mmp-9) Levels In Peritoneal Fluid Of Endometriosis On Mice Model

In: JKM (Jurnal Kebidanan Malahayati) · 2021 · vol. 8(1) , pp. 79–86 · doi:10.33024/jkm.v8i1.5847 · W4387416846
article OA: bronze CC0 ⤵ 1 in-corpus citation
AI-generated summary by claude@2026-06, 2026-06-08

Genistein administration decreased matrix metalloproteinase-2 and -9 levels in the peritoneal fluid of a mouse model of endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-08 · read from full text

The paper experimentally tested whether genistein reduces matrix metalloproteinases MMP-2 and MMP-9 in peritoneal fluid from a mouse model of endometriosis, using eight groups including negative/positive controls and genistein doses from 50 to 500 mg/day. MMP-2 and MMP-9 levels were quantified by ELISA, and results were analyzed with ANOVA, Tukey, and regression. Genistein decreased MMP-2 at the lowest doses reported (notably 50 mg/day and 100 mg/day, and also 400 mg/day among the lowest values) and decreased MMP-9 at 50–400 mg/day, with the lowest MMP-9 levels observed at 50 and 100 mg/day. The study’s main limitation explicitly acknowledged is that further work is needed in another animal model (the authors mention rabbits) to evaluate genistein’s effects beyond mice. This paper is centrally about endometriosis—genistein’s effect on MMP-2 and MMP-9 levels in peritoneal fluid in a mouse model of endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Latar Belakang: Matrix metalloproteinases (MMPs) mempengaruhi progesivitas endometriosis, dalam invasi, perkembangan dan metastasis endometriosis. Penururan kadar MMP-2 dan MMP-9 merupakan terapi yang tepat untuk kasus endometriosis menggunakan terapi hormonal alami yaitu genistein. Tujuan: Penelitian ini bertujuan untuk mengetahui pemberian genistein dapat menurunkan kadar MMP-2 dan MMP-9 dalam cairan peritoneal mencit (Mus musculus) model endometriosis. Metode: Penelitian ini merupakan penelitian eksperimental yang dilakukan di Laboratorium Fisiologi Reproduksi Embriologi Fakultas Kedokteran Hewan Universitas Airlangga Surabaya dan Laboratorium Fisiologi Fakultas Kedokteran Universitas Brawijaya Malang. Sampel menggunakan mencit (Mus musculus) model endometriosis. Penelitian dibagi menjadi 8 kelompok, yaitu : kontrol negatif, kontrol positif dan perlakuan pemberian genistein dosis 50 mg/hari, 100 mg/hari, 200 mg/hari, 300 mg/hari, 400 mg/hari, 500 mg/hari. Pengukuran kadar MMP-2 dan MMP-9 menggunakan ELISA kit. Data hasil pengamatan dianalisis dengan uji ANOVA, Tukey dan Regresi. Hasil: Genistein mampu menurunkan kadar MMP-2 terendah pada dosis 50 mg/hari (5.61±0.69 ng/mL), 100 mg/hari (4.91±0.59 ng/mL) dan 400 mg/hari (4.95±0.32 ng/mL) bila dibandingkan dengan perlakuan dosis yang lain. Genistein mampu menurunkan kadar MMP-9 terendah pada dosis 50 mg/hari (1.69±0.45 ng/mL), 100 mg/hari (1.29±0.32 ng/mL), 200 mg/hari (1.84±0.25 ng/mL) dan 400 mg/hari (1.42±0.11 ng/mL) bila dibaningkan dengan perlakuan dosis yang lain. Kesimpulan: Genistein dapat menurunkan kadar MMP-2 dan MMP-9 dalam cairan peritoneal mencit (Mus musculus) model endometriosis. Saran: Perlu studi lanjut untuk melihat pengaruh genistein pada hewan coba kelinci Kata Kunci: Endometriosis, Genistein, MMP-2, MMP-9 ABSTRACT Background: Matrix metalloproteinases (MMPs) affect the progression of endometriosis, in the invasion , development , and metastasis of endometriosis. Reducing levels of MMP-2 and MMP-9 is an appropriate therapy for endometriosis cases using natural hormonal therapy, namely genistein. Purpose: To know the effect of genistein on the level of MMP-2 and MMP-9 in peritoneal fluid of endometriosis mice model. Method: The design of this study was experimental, had been performed in Reproductive Physiology and Embryology Laboratory, Veterinary Medical Faculty of Airlangga University Surabaya and Physiology Laboratory, Medical Faculty of Brawijaya University Malang. The animal model was divided the 8 groups: negative group ,positive group, and treated group with genistein doses of 50 mg/day, 100 mg/day, 200 mg/day, 300 mg/day, 400 mg/day, and 500 mg /day (human dose). The measurement of MMP-2 and MMP-9 levels using ELISA kits. The data were analyzed with ANOVA, Tukey, and Regression tests. Result: Genistein was able to decrease the MMP-2 level in the lowest dose 50 mg/day (5.61±0.69 ng/mL), 100 mg/day (4.91±0.59 ng/mL) and 400 mg/day (4.95±0.32 ng/mL) when compared with other treatment dose. Genistein was able to decrease the MMP-9 level in the lowest dose 50 mg/day (1.69±0.45 ng/mL), 100 mg/day (1.29±0.32 ng/mL), 200 mg/day (1.84±0.25 ng/ mL) and 400 mg/day (1.42±0.11 ng/mL) when compared with other treatment doses. Conclusion: Genistein may decrease MMP-2 and MMP-9 levels in peritoneal fluid of endometriosis mice model. Suggestion: Further study is needed to see the effect of genistein on rabbit experimental animals. Keywords: Endometriosis, Genistein, MMP-2, MMP-9
Full text 9,450 characters · extracted from oa-doi-fallback · 7 sections · click to expand

Abstract

Latar Belakang: Matrix metalloproteinases (MMPs) mempengaruhi progesivitas endometriosis, dalam invasi, perkembangan dan metastasis endometriosis. Penururan kadar MMP-2 dan MMP-9 merupakan terapi yang tepat untuk kasus endometriosis menggunakan terapi hormonal alami yaitu genistein. Tujuan: Penelitian ini bertujuan untuk mengetahui pemberian genistein dapat menurunkan kadar MMP-2 dan MMP-9 dalam cairan peritoneal mencit (Mus musculus) model endometriosis. Metode: Penelitian ini merupakan penelitian eksperimental yang dilakukan di Laboratorium Fisiologi Reproduksi Embriologi Fakultas Kedokteran Hewan Universitas Airlangga Surabaya dan Laboratorium Fisiologi Fakultas Kedokteran Universitas Brawijaya Malang. Sampel menggunakan mencit (Mus musculus) model endometriosis. Penelitian dibagi menjadi 8 kelompok, yaitu : kontrol negatif, kontrol positif dan perlakuan pemberian genistein dosis 50 mg/hari, 100 mg/hari, 200 mg/hari, 300 mg/hari, 400 mg/hari, 500 mg/hari. Pengukuran kadar MMP-2 dan MMP-9 menggunakan ELISA kit. Data hasil pengamatan dianalisis dengan uji ANOVA, Tukey dan Regresi. Hasil: Genistein mampu menurunkan kadar MMP-2 terendah pada dosis 50 mg/hari (5.61±0.69 ng/mL), 100 mg/hari (4.91±0.59 ng/mL) dan 400 mg/hari (4.95±0.32 ng/mL) bila dibandingkan dengan perlakuan dosis yang lain. Genistein mampu menurunkan kadar MMP-9 terendah pada dosis 50 mg/hari (1.69±0.45 ng/mL), 100 mg/hari (1.29±0.32 ng/mL), 200 mg/hari (1.84±0.25 ng/mL) dan 400 mg/hari (1.42±0.11 ng/mL) bila dibaningkan dengan perlakuan dosis yang lain. Kesimpulan: Genistein dapat menurunkan kadar MMP-2 dan MMP-9 dalam cairan peritoneal mencit (Mus musculus) model endometriosis. Saran: Perlu studi lanjut untuk melihat pengaruh genistein pada hewan coba kelinci Kata Kunci: Endometriosis, Genistein, MMP-2, MMP-9

Abstract

Background: Matrix metalloproteinases (MMPs) affect the progression of endometriosis, in the invasion , development , and metastasis of endometriosis. Reducing levels of MMP-2 and MMP-9 is an appropriate therapy for endometriosis cases using natural hormonal therapy, namely genistein. Purpose: To know the effect of genistein on the level of MMP-2 and MMP-9 in peritoneal fluid of endometriosis mice model.

Method

The design of this study was experimental, had been performed in Reproductive Physiology and Embryology Laboratory, Veterinary Medical Faculty of Airlangga University Surabaya and Physiology Laboratory, Medical Faculty of Brawijaya University Malang. The animal model was divided the 8 groups: negative group ,positive group, and treated group with genistein doses of 50 mg/day, 100 mg/day, 200 mg/day, 300 mg/day, 400 mg/day, and 500 mg /day (human dose). The measurement of MMP-2 and MMP-9 levels using ELISA kits. The data were analyzed with ANOVA, Tukey, and Regression tests.

Result

Genistein was able to decrease the MMP-2 level in the lowest dose 50 mg/day (5.61±0.69 ng/mL), 100 mg/day (4.91±0.59 ng/mL) and 400 mg/day (4.95±0.32 ng/mL) when compared with other treatment dose. Genistein was able to decrease the MMP-9 level in the lowest dose 50 mg/day (1.69±0.45 ng/mL), 100 mg/day (1.29±0.32 ng/mL), 200 mg/day (1.84±0.25 ng/ mL) and 400 mg/day (1.42±0.11 ng/mL) when compared with other treatment doses.

Conclusion

Genistein may decrease MMP-2 and MMP-9 levels in peritoneal fluid of endometriosis mice model. Suggestion: Further study is needed to see the effect of genistein on rabbit experimental animals.

Keywords

Endometriosis, Genistein, MMP-2, MMP-9

Keywords

Full Text: PDFReferences Adamyan, LV, Manukyan, LM, Loginova, ON, Arslanyan, KN, & Zayratyants, VO(2020). The role of matrix metalloproteinases in the pathogenesis of endometriosis (Literature review). In Russian Journal of Human Reproduction (Vol. 26, Issue 2, pp. 95–103). https://doi.org/10.17116/repro20202602195 Banerjee, S., Li, Y., Wang, Z., & Sarkar, FH (2008). Multi-targeted therapy of cancer by genistein. Cancer Letters , 269 (2), 226–242. https://doi.org/10.1016/j.canlet.2008.03.052 Brinckerhoff, CE (2017). Regulation of Matrix Metalloproteinase (MMP) Gene Expression. In Matrix Metalloproteinases in Health and Disease (pp. 31–63). https://doi.org/10.1142/9789813207554_0003 Collette, T., Maheux, R., Mailloux, J., & Akoum, A. (2006). Increased expression of matrix metalloproteinase-9 in the eutopic endometrial tissue of women with endometriosis. Human Reproduction , 21 (12), 3059–3067. https://doi.org/10.1093/humrep/del297 Fassbender, A., Dorien, O., De Moor, B., Waelkens, E., Meuleman, C., Tomassetti, C., Peeraer, K., & D'Hooghe, T. (2014). Biomarkers of endometriosis. Endometriosis: Pathogenesis and Treatment , 99 (4), 321–339. https://doi.org/10.1007/978-4-431-54421-0_20 Kayisli, UA, Aksu, CAH, Berkkanoglu, M., & Arici, A. (2002). Estrogenicity of isoflavones on human endometrial stromal and glandular cells. In Journal of Clinical Endocrinology and Metabolism (Vol. 87, Issue 12, pp. 5539–5544). https://doi.org/10.1210/jc.2002-020716 Lakshman, M., Xu, L., Ananthanarayanan, V., Cooper, J., Takimoto, CH, Helenowski, I., Pelling, JC, & Bergan, RC (2008). Dietary genistein inhibits metastasis of human prostate cancer in mice. In Cancer Research (Vol. 68, Issue 6, pp. 2024–2032). https://doi.org/10.1158/0008-5472.CAN-07-1246 Leyland, N., Casper, R., Laberge, P., Singh, SS, Allen, L., Arendas, K., Allaire, C., Awadalla, A., Best, C., Contestabile, E., Dunn , S., Heywood, M., Leroux, N., Potestio, F., Rittenberg, DA, Soucy, R., Wolfman, WL, & Senikas, V. (2010). Endometriosis: Diagnosis and Management. Journal of Obstetrics and Gynecology Canada , 32 (7), S1–S3. https://doi.org/10.1016/S1701-2163(16)34589-3 Mendis, E., Kim, MM, Rajapakse, N., & Kim, SK (2009). The inhibitory mechanism of a novel cationic glucosamine derivative against MMP-2 and MMP-9 expressions. In Bioorganic and Medicinal Chemistry Letters (Vol. 19, Issue 10, pp. 2755–2759). https://doi.org/10.1016/j.bmcl.2009.03.126 Noori-Daloii, MR, Saffari, M., Saydi Dinekabodi, O., Rahmani, B., Noori-Daloii, AR, Salehi, AH, & Ghazarian, A. (2012). Study of antimetastatic effect of genistein through inhibition of expression of matrix metalloproteinase in A-549 cell line. Journal of Sciences, Islamic Republic of Iran , 23 (2), 115–122. Prakash, D., & Gupta, C. (2011). Role of phytoestrogens as nutraceuticals in human health: A review. BioTechnology: An Indian Journal , 5 (3), 171–178. Sha, GH, & Lin, SQ (2008). Genistein inhibits proliferation of human endometrial endothelial cells in vitro. Chinese Medical Sciences Journal , 23 (1), 49–53. https://doi.org/10.1016/S1001-9294(09)60010-9 Shaco-Levy, R., Sharabi, S., Benharroch, D., Piura, B., & Sion-Vardy, N. (2008). Matrix metalloproteinases 2 and 9, E-cadherin, and -catenin expression in endometriosis, lowgrade endometrial carcinoma and nonneoplastic eutopic endometrium. In European Journal of Obstetrics and Gynecology and Reproductive Biology (Vol. , Issue 2, pp. 226–232). https://doi.org/10.1016/j.ejogrb.2008.01.004 Soares, SR, Martínez-Varea, A., Hidalgo-Mora, J. J., & Pellicer, A. (2012). Pharmacologic therapies in endometriosis: A systematic review. Fertility and Sterility , 98 (3), 529–555. https://doi.org/10.1016/j.fertnstert.2012.07.1120 Sutrisno. 2014. The Effect of Implant Origin on the Incidence of Peritoneal Endometriosis, A Study to Design a Mice Model of Endometriosis. Laboratory of Obstetrics and Gynecology FK Brawijaya University, Malang Sutrisno, S., Mastryagung, D., Khairiyah, R. , Tridiyawati , F., Dewi, N., Hidayati, D., Noorhamdani, N., Santoso, S., 2014. The effects of genistein on estrogen receptor expression , cell proliferation and apoptosis in endometriosis cell culture. Journal of Experimental and Integrative Medicine. 4 (3 ) : 1-6 Sutrisno, S., Mariyani, M., Herawati I., Rinata, E. , Jehanara , J., Yueniwati, Y., Nurdiana, N., Noorhamdani, N., Santoso, S., 2014. The effects of genistein as inflammatory and antiangiogenesis in primary endometriosis cell culture. Asian Pacific Journal of Reproduction . 3 (4 ) : 1-6 Weigel, MT, Krämer, J., Schem, C., Wenners, A. , Alkatout , I., Jonat, W., Maass, N., & Mundhenke, C. (2012). Differential expression of MMP-2, MMP-9 and PCNA in endometriosis and endometrial carcinoma. European Journal of Obstetrics Gynecology and Reproductive Biology , 160 (1), 74–78. https://doi.org/10.1016/j.ejogrb.2011.09.040 Yavuz, E., Oktem, M., Ensiler, I., Toru, SA, and Zeyneloglu, HB, 2006. Genistein Causes Regression of Endometriotic Implants in the Rat Model. Fertility and Sterility . 88(2 ) : 1129-1134 Zhang, H., Li, M., Wang, F., Liu, S., Li, J., Wen, Z. , & Zhao, X. (2010). Endometriotic epithelial cells induce MMPs expression in endometrial stromal cells via an NFB-dependent pathway. In Gynecological Endocrinology (Vol. 26, Issue 6, pp. 456–467). https://doi.org/10.3109/09513590903366988 DOI: https://doi.org/10.33024/jkm.v8i1.5847 Refbacks - There are currently no refbacks. Copyright (c) 2022 Jurnal Kebidanan Malahayati Policies | Submissions | Other | | Focus and Scope Section Policies Peer Review Process Publication Frequency Open Access Policy | Online Submissions Author Guidelines Copyright Notice Privacy Statement Author Fees | Journal Sponsorship Journal History Site Map About this Publishing System |

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (18)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK